Radiotherapy and Oncology最新文献_第7页

Highly-Multiplex Detection of Plasma Cell-Free High-Risk Human Papillomavirus DNA for Rare Genotypes 罕见基因型无浆细胞高危人乳头瘤病毒DNA的高度多重检测

IF 5.3 1区医学

Radiotherapy and Oncology Pub Date : 2026-03-01 Epub Date: 2026-04-09 DOI: 10.1016/S0167-8140(26)00184-2

Janita Basit , Payton Clark , Alfred Kotarja , Shauna R Campbell , Neil M Woody , Tamara A Sussman , Kyunghee Burkitt , Jessica L Geiger , Hannah Wang , Timothy A Chan , Shlomo A Koyfman , Jacob A Miller

引用次数: 0

REALKEY study: patient-reported outcomes in recurrent/metastatic head and neck cancer treated with first-line immunotherapy +/- chemotherapy REALKEY研究：患者报告的一线免疫治疗+/-化疗治疗复发/转移性头颈癌的结局

IF 5.3 1区医学

Radiotherapy and Oncology Pub Date : 2026-03-01 Epub Date: 2026-04-09 DOI: 10.1016/S0167-8140(26)00255-0

Sandra Llop , Álvaro Garcia Bauto , Gonzalo Peon , Sara Tous , Zara Vidales , Maria Plana , Arnau Guasch , Matteo Carpani , Luigi Lorini , Andrea Botticelli , Pierlu Bonomo , Alessandra Cassano , Alicia Tosoni , Maria Cossurocca , Paolo Bossi , Marc Oliva

引用次数: 0

Deep learning multi-toxicity prediction model in head and neck cancer radiotherapy patients 头颈部肿瘤放疗患者的深度学习多毒性预测模型

IF 5.3 1区医学

Radiotherapy and Oncology Pub Date : 2026-03-01 Epub Date: 2026-04-09 DOI: 10.1016/S0167-8140(26)00198-2

Lisanne V van Dijk , Daniel C MacRae , Luuk van der Hoek , Suzanne P.M. de Vette , Hendrike Neh , Johannes A Langendijk , Nanna M Sijtsema , Peter van Ooijen

引用次数: 0

A phase III RCT comparing xerostomia after tubarial salivary gland sparing IMRT versus standard IMRT in oropharyngeal SCC- preliminary results 一项III期随机对照试验比较了口咽鳞状细胞癌保留输卵管涎腺的IMRT与标准IMRT后口干症的初步结果

IF 5.3 1区医学

Radiotherapy and Oncology Pub Date : 2026-03-01 Epub Date: 2026-04-09 DOI: 10.1016/S0167-8140(26)00225-2

Ahitagni Biswas , Sudatta Mandal , Suman Bhasker , Ashish Binjola , Seema Sharma , Vivek Ghosh , Swarnaditya Roy , Raja Pramanik , Aanchal Kakkar , Chandraprakash Prasad , Madhavi Tripathi , Kapil Sikka , Chirom Amit Singh , Krithika Rangarajan , Senthil Kumaran , Chandrasekhar Bal , Rajeev Kumar Malhotra

引用次数: 0

Integrative Nanotherapy Using Strictosidine–TiO2 Nanoparticles for Targeted Apoptosis and Angiogenesis Inhibition in Oral Carcinoma 应用缩藤皂苷- tio2纳米颗粒联合纳米疗法抑制口腔癌细胞凋亡和血管生成

IF 5.3 1区医学

Radiotherapy and Oncology Pub Date : 2026-03-01 Epub Date: 2026-04-09 DOI: 10.1016/S0167-8140(26)00218-5

Bhavana H H , Chandan Shivamallu , Chandan Dharmashekar , Ashwini P , Shivaprasad Kollur

引用次数: 0

Are the CTV-to-PTV margins currently used in online adaptive radiotherapy for prostate cancer too large? The impact of the distribution of microscopic disease on treatment margin requirements 目前用于前列腺癌在线适应性放疗的ctv - ptv边缘是否过大？微观疾病分布对治疗裕度要求的影响。

IF 5.3 1区医学

Radiotherapy and Oncology Pub Date : 2026-03-01 Epub Date: 2025-12-19 DOI: 10.1016/j.radonc.2025.111351

Mathijs G. Dassen , Marcel van Herk , Marnix G. Witte , Tomas Janssen , Floris Pos , Uulke A. van der Heide

{"title":"Are the CTV-to-PTV margins currently used in online adaptive radiotherapy for prostate cancer too large? The impact of the distribution of microscopic disease on treatment margin requirements","authors":"Mathijs G. Dassen , Marcel van Herk , Marnix G. Witte , Tomas Janssen , Floris Pos , Uulke A. van der Heide","doi":"10.1016/j.radonc.2025.111351","DOIUrl":"10.1016/j.radonc.2025.111351","url":null,"abstract":"<div><h3>Purpose</h3><div>Planning target volume (PTV) margin recipes assume all parts of the target are equally important. For the prostate clinical target volume (CTV) this is invalid. We evaluated the impact of the spatial probability distribution of microscopic disease in the prostate on CTV-to-PTV margins.</div></div><div><h3>Materials and methods</h3><div>A prostate with a volume of 44 cm<sup>3</sup> was defined as CTV<sub>prostate</sub>. Homogenous dose distributions were created with margins ranging 0–5 mm. The gross tumor volume (GTV) was assumed covered with a separate margin. Microscopic satellites were sampled within the CTV<sub>prostate</sub> from a histopathology-based probability distribution for a range of numbers (1–10) and sizes (0.02–0.2 cm<sup>3</sup>) to define CTV<sub>satellites</sub>. Geometric errors were sampled from a 3D Gaussian distribution, simulating online adaptive treatment of 5 fractions. Each CTV was shifted with respect to the dose according to each total error. The PTV margin ensuring 95 % of the prescribed dose to the CTV<sub>satellites</sub> in 90 % of simulations was determined and compared with CTV<sub>prostate</sub>.</div></div><div><h3>Results</h3><div>For systematic errors with width (Σ) 0.5 mm and random errors with width (σ<sub>r</sub>) 1.5 mm, the margin for the CTV<sub>prostate</sub> was 3 mm, whereas for each definition of CTV<sub>satellites</sub> this margin was 0–1 mm. For σ<sub>r</sub> = 2.7 mm, a margin of 5 mm was adequate for the CTV<sub>prostate</sub> and 2–3 mm for all except the most favourable and unfavourable CTV<sub>satellites</sub> definition.</div></div><div><h3>Conclusion</h3><div>The CTV-to-PTV margins used in online adaptive radiotherapy for prostate cancer can be reduced by ∼2 mm, if the GTV is covered with an adequate margin.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"216 ","pages":"Article 111351"},"PeriodicalIF":5.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145805234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stage-adjusted forecasting of radiotherapy demand and outcome benefits across income groups: Estimating survival and local control gains by 2050 不同收入群体放疗需求和结果收益的分期调整预测：估计到2050年的生存和局部控制收益。

IF 5.3 1区医学

Radiotherapy and Oncology Pub Date : 2026-03-01 Epub Date: 2025-11-22 DOI: 10.1016/j.radonc.2025.111303

Mengqi Zhou , Dania Abu Awwad , Geoffrey Paul Delaney , Vikneswary Batumalai , Aba Scott , Eduardo Zubizarreta , Yavuz Anacak , Soehartati Gondhowiardjo , Tiara B. Mayang Permata , Mei Ling Yap

{"title":"Stage-adjusted forecasting of radiotherapy demand and outcome benefits across income groups: Estimating survival and local control gains by 2050","authors":"Mengqi Zhou , Dania Abu Awwad , Geoffrey Paul Delaney , Vikneswary Batumalai , Aba Scott , Eduardo Zubizarreta , Yavuz Anacak , Soehartati Gondhowiardjo , Tiara B. Mayang Permata , Mei Ling Yap","doi":"10.1016/j.radonc.2025.111303","DOIUrl":"10.1016/j.radonc.2025.111303","url":null,"abstract":"<div><h3>Background</h3><div>Radiotherapy is a vital component of cancer care, yet access is limited. Global estimates often overlook cancer stage variability across countries with different income levels. This study assesses the supply–demand gap for megavoltage radiotherapy machines (MVMs) from 2012 to 2022 and projects the survival and local control benefits achievable by meeting optimal radiotherapy needs by 2050.</div></div><div><h3>Methods</h3><div>Global cancer data were from GLOBOCAN 2022. A validated, stage-adjusted radiotherapy utilisation model was adapted using available cancer stage data from LMICs for each geographical region. Population-based models estimating local control and survival benefit from radiotherapy were also stage-adjusted. The overall shortfall was calculated as patients not receiving treatment due to limited MVM availability. Corresponding outcome gaps were estimated by multiplying shortfall cases by their respective benefit percentages.</div></div><div><h3>Results</h3><div>Radiotherapy demand increased by 2.4 million cases from 2012 to 2022. Optimising access would yield survival benefits for >860,000 people annually and improved local control for 3.5 million cases annually. Lower-middle-income countries are estimated to derive the highest population-based benefits in local control (10.65 %) and survival (4.94 %). The number of patients missing radiotherapy is projected to reach 7.9 million by 2050, creating a global local control gap of 1.2 million and a survival gap of 500,000 cases per year.</div></div><div><h3>Conclusion</h3><div>This study highlights the urgent need for enhanced policies and expanded infrastructure to address radiotherapy disparities, particularly in LMICs, to improve local control and survival outcomes.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"216 ","pages":"Article 111303"},"PeriodicalIF":5.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145597250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How can a radiation oncology society support its members and the community to help reduce the carbon footprint of radiation oncology? 放射肿瘤学学会如何支持其会员和社会各界帮助减少放射肿瘤学的碳足迹？

IF 5.3 1区医学

Radiotherapy and Oncology Pub Date : 2026-03-01 Epub Date: 2025-12-22 DOI: 10.1016/j.radonc.2025.111361

Rachel Allcock , Kari Tanderup , Jenny Bertholet , Amanda Webster , Robert Chuter

{"title":"How can a radiation oncology society support its members and the community to help reduce the carbon footprint of radiation oncology?","authors":"Rachel Allcock , Kari Tanderup , Jenny Bertholet , Amanda Webster , Robert Chuter","doi":"10.1016/j.radonc.2025.111361","DOIUrl":"10.1016/j.radonc.2025.111361","url":null,"abstract":"<div><h3>Background</h3><div>Climate change is an escalating crisis with significant implications for public health and healthcare services. We aimed to survey radiation oncology (RO) professionals on their understanding and concerns about climate change and the role of ESTRO in addressing the crisis.</div></div><div><h3>Materials and Methods</h3><div>A 14-item survey covering environmental impact of RO activities, personal actions, and expectations of ESTRO’s responses to the climate crisis was developed, validated, and disseminated to RO professionals by email and online platforms.</div></div><div><h3>Results</h3><div>706 responses were received out of 9,781 ESTRO members. Concern about climate change was indicated by 90% of respondents and 94% had changed their personal lives to help combat the climate crisis. Yet 50% of respondents could not identify RO’s main contributors to climate change. 39% reported positive attitudes to online conferences and 79% agreed that ESTRO should offer digital participation to reduce the carbon impact of travel. Reported barriers to digital participation were mainly related to lack of face-to-face interaction.</div><div>Although additional time was the most common barrier to reducing flying for work-related trips, 47 % of respondents were willing to travel by train for ≥ 7 h to an ESTRO conference. The majority of respondents (82 %) agreed that ESTRO should ‘Increase engagement with manufacturers around environmental sustainability’.</div></div><div><h3>Conclusion</h3><div>Our results reveal strong concern about the climate crisis among RO professionals, willingness to implement change, lack of knowledge about climate impact of RO and support for ESTRO actions to support its members and the community in these efforts.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"216 ","pages":"Article 111361"},"PeriodicalIF":5.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Palliative Radiotherapy with 27 Gy in 6 Fractions for Head and Neck Cancer: A Single-Centre Experience of Toxicities and Clinical Outcomes 头颈癌的6段27 Gy姑息放疗：毒性和临床结果的单中心经验

IF 5.3 1区医学

Radiotherapy and Oncology Pub Date : 2026-03-01 Epub Date: 2026-04-09 DOI: 10.1016/S0167-8140(26)00258-6

Amani A Chowdhury , Amit Gupta , Ashitha Ashraf , Saira Khalique , Kevin Chiu

引用次数: 0

CtDNA as a biomarker in Salivary Gland Cancer (SAGACE trial) CtDNA作为唾液腺癌的生物标志物（SAGACE试验）

IF 5.3 1区医学

Radiotherapy and Oncology Pub Date : 2026-03-01 Epub Date: 2026-04-09 DOI: 10.1016/S0167-8140(26)00170-2

Federica Riva , Francesca Gaino , Erika Stucchi , Cristina Gurizzan , Riccardo Zadro , Sergio Marchini , Lara Paracchini , Luigi Lorini , Carlo Resteghini , Giuseppe Mercante , Caterina Giannitto , Giuseppe Spriano , Silvia Uccella , Martina Iuzzolino , Paolo Bossi

引用次数: 0